vs
Side-by-side financial comparison of Immunocore Holdings plc (IMCR) and ROGERS CORP (ROG). Click either name above to swap in a different company.
ROGERS CORP is the larger business by last-quarter revenue ($200.5M vs $104.5M, roughly 1.9× Immunocore Holdings plc). On growth, Immunocore Holdings plc posted the faster year-over-year revenue change (24.3% vs 5.2%). ROGERS CORP produced more free cash flow last quarter ($1.1M vs $-35.5M). Over the past eight quarters, Immunocore Holdings plc's revenue compounded faster (21.7% CAGR vs -3.3%).
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
IMCR vs ROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $104.5M | $200.5M |
| Net Profit | — | $4.5M |
| Gross Margin | 97.4% | 32.2% |
| Operating Margin | -18.8% | — |
| Net Margin | — | 2.2% |
| Revenue YoY | 24.3% | 5.2% |
| Net Profit YoY | — | 421.4% |
| EPS (diluted) | $-0.61 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $104.5M | $201.5M | ||
| Q3 25 | $103.7M | $216.0M | ||
| Q2 25 | $98.0M | $202.8M | ||
| Q1 25 | $93.9M | $190.5M | ||
| Q4 24 | $84.1M | $192.2M | ||
| Q3 24 | $80.2M | $210.3M | ||
| Q2 24 | $75.4M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | — | $4.6M | ||
| Q3 25 | $-177.0K | $8.6M | ||
| Q2 25 | $-10.3M | $-73.6M | ||
| Q1 25 | $5.0M | $-1.4M | ||
| Q4 24 | — | $-500.0K | ||
| Q3 24 | $8.7M | $10.7M | ||
| Q2 24 | $-11.6M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | 97.4% | 31.5% | ||
| Q3 25 | 99.5% | 33.5% | ||
| Q2 25 | 98.9% | 31.6% | ||
| Q1 25 | 99.1% | 29.9% | ||
| Q4 24 | 99.6% | 32.1% | ||
| Q3 24 | 99.4% | 35.2% | ||
| Q2 24 | 97.7% | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | -18.8% | 3.5% | ||
| Q3 25 | -6.9% | 7.3% | ||
| Q2 25 | -15.2% | -33.3% | ||
| Q1 25 | -3.9% | -0.2% | ||
| Q4 24 | -23.1% | -6.6% | ||
| Q3 24 | -10.6% | 6.9% | ||
| Q2 24 | -21.2% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | -0.2% | 4.0% | ||
| Q2 25 | -10.5% | -36.3% | ||
| Q1 25 | 5.4% | -0.7% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | 10.9% | 5.1% | ||
| Q2 24 | -15.4% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $-0.61 | $0.20 | ||
| Q3 25 | $0.00 | $0.48 | ||
| Q2 25 | $-0.20 | $-4.00 | ||
| Q1 25 | $0.10 | $-0.08 | ||
| Q4 24 | $-0.47 | $-0.04 | ||
| Q3 24 | $0.17 | $0.58 | ||
| Q2 24 | $-0.23 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $864.2M | $195.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $381.0M | $1.2B |
| Total Assets | $1.1B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $864.2M | $197.0M | ||
| Q3 25 | $892.4M | $167.8M | ||
| Q2 25 | $882.8M | $157.2M | ||
| Q1 25 | $837.0M | $175.6M | ||
| Q4 24 | $820.4M | $159.8M | ||
| Q3 24 | $901.3M | $146.4M | ||
| Q2 24 | $859.6M | $119.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $438.7M | — | ||
| Q2 24 | $452.5M | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $381.0M | $1.2B | ||
| Q3 25 | $396.6M | $1.2B | ||
| Q2 25 | $388.5M | $1.2B | ||
| Q1 25 | $378.5M | $1.3B | ||
| Q4 24 | $360.7M | $1.3B | ||
| Q3 24 | $377.8M | $1.3B | ||
| Q2 24 | $359.1M | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $1.1B | $1.5B | ||
| Q1 25 | $1.0B | $1.5B | ||
| Q4 24 | $1.0B | $1.5B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.0B | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.16× | — | ||
| Q2 24 | 1.26× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-32.7M | $5.8M |
| Free Cash FlowOCF − Capex | $-35.5M | $1.1M |
| FCF MarginFCF / Revenue | -34.0% | 0.5% |
| Capex IntensityCapex / Revenue | 2.8% | 2.3% |
| Cash ConversionOCF / Net Profit | — | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | $-15.1M | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $-32.7M | $46.9M | ||
| Q3 25 | $-4.5M | $28.9M | ||
| Q2 25 | $26.0M | $13.7M | ||
| Q1 25 | $435.0K | $11.7M | ||
| Q4 24 | $-14.0M | $33.7M | ||
| Q3 24 | $21.1M | $42.4M | ||
| Q2 24 | $23.5M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $-35.5M | $42.2M | ||
| Q3 25 | $-5.2M | $21.2M | ||
| Q2 25 | $25.6M | $5.6M | ||
| Q1 25 | $137.0K | $2.1M | ||
| Q4 24 | $-17.5M | $18.3M | ||
| Q3 24 | $20.3M | $25.2M | ||
| Q2 24 | $23.1M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | -34.0% | 20.9% | ||
| Q3 25 | -5.0% | 9.8% | ||
| Q2 25 | 26.1% | 2.8% | ||
| Q1 25 | 0.1% | 1.1% | ||
| Q4 24 | -20.9% | 9.5% | ||
| Q3 24 | 25.3% | 12.0% | ||
| Q2 24 | 30.7% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 2.8% | 2.3% | ||
| Q3 25 | 0.7% | 3.6% | ||
| Q2 25 | 0.4% | 4.0% | ||
| Q1 25 | 0.3% | 5.0% | ||
| Q4 24 | 4.3% | 8.0% | ||
| Q3 24 | 1.0% | 8.2% | ||
| Q2 24 | 0.4% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.09× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.42× | 3.96× | ||
| Q2 24 | — | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
